AM PEF: Weakly mean morning peak expiratory flow; FEV1: Forced expiratory volume in 1 s; FVC: Forced vital capacity; LTRA: Leukotriene-receptor antagonist. Chronic overproduction of cysteinyl ...

Findings for matched groups of patients with obesity and diabetes taking first-generation GLP-1 RA or undergoing bariatric metabolic surgery. (HealthDay News) — Glucagon-like peptide-1 receptor ...

Reductions in alcohol intake noted in high and low consumers; no significant difference seen in percentage reductions for men and women. (HealthDay News) — Glucagon-like peptide-1 receptor ...

HealthDay News — Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are tied to a reduction in alcohol intake, according to a research letter recently published in Diabetes, Obesity and Metabolism ...

Glucagon-like peptide-1 receptor agonists are linked to a reduction in alcohol intake. HealthDay News — Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are tied to a reduction in alcohol intake, ...

THURSDAY, May 15, 2025 (HealthDay News) — Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being treated for diabetes and obesity, ...

The proportion of adult managed care organizations with availability varied from 24 to 100% for SGLT2 inhibitors and 0 to 99% for GLP-1 receptor agonists. HealthDay News — Many Medicaid enrollees with ...

with or without a low-dose inhaled glucocorticoid or leukotriene-receptor antagonist. Participants were randomly assigned in a 1:1 ratio to a fixed-dose combination of 180 μg of albuterol and 160 ...

Prostaglandin E 2 (PGE 2), a bioactive lipid derived from arachidonic acid, mediates a broad range of physiological processes through four G protein-coupled receptor (GPCR) subtypes: EP1–EP4.

Back to Healio NATIONAL HARBOR, Md. — GLP-1 receptor agonists are effective weight-loss medications, but they may also decrease muscle mass, raising concerns about the long-term effects of these ...